What does remission mean for Melanoma and how is it monitored

Understanding Remission and Monitoring in Melanoma

What Remission Means for Melanoma

Remission in melanoma refers to a state where there is no evidence of disease (NED) — meaning that after treatment, doctors cannot find any signs of cancer in your body based on physical exams, imaging tests, or biopsies.

It's important to understand that remission has different meanings depending on your situation:

Complete Remission: All visible tumors have been removed or destroyed, and no cancer can be detected by current testing methods.

Partial Remission: Some cancer remains, but it has shrunk significantly in response to treatment.

However, remission doesn't necessarily mean "cured." Melanoma can sometimes return even after successful initial treatment, which is why ongoing monitoring is essential.

---

How Remission is Monitored

According to the NCCN Guidelines for Patients: Melanoma (2025), follow-up care is a critical part of your treatment plan. Here's what monitoring typically involves:

Physical Examinations

Your healthcare provider will examine your skin and lymph nodes regularly. The NCCN Guidelines recommend:

• At least once every year for most patients
• More frequently if you're at higher risk for recurrence (based on your stage and other factors)

During these exams, your doctor looks for:

• New or changing moles or spots on your skin
• Enlarged lymph nodes in the lymph node basin (the group of lymph nodes near where your original melanoma was located)

Self-Examinations

You play an active role in monitoring. The NCCN Guidelines emphasize that you should perform regular skin self-exams using the ABCDE rule:

• Asymmetry – One half of a mole doesn't match the other
• Border – Edges are irregular or hard to define
• Color – Not uniform throughout (may have brown, black, pink, red, white, or blue patches)
• Diameter – Larger than 6mm (about the size of a pencil eraser)
• Evolving – The spot or mole changes in size, shape, or color over time

Imaging Tests

The frequency and type of imaging depend on your stage and risk factors:

• CT scans (computed tomography) or PET scans may be used if you had regional or metastatic disease
• Lymphatic mapping (using dyes and radioactive substances) may be done to identify if cancer has spread to lymph vessels
• If you had a positive sentinel lymph node biopsy (meaning cancer was found in a lymph node), your doctor might consider more imaging

Biopsy if Needed

If a suspicious spot appears during follow-up, your doctor may perform a skin biopsy (removing a small sample of tissue) to confirm whether it's cancer or scar tissue.

---

How Often You'll Be Monitored

According to the NCCN Guidelines, how often you receive follow-up testing depends on how likely it is that the cancer will return. This is based on:

• Your original cancer stage
• How deep the melanoma was (Breslow thickness)
• Whether it had spread to lymph nodes
• Other risk factors in your pathology report

Your care team will explain a personalized follow-up schedule for your specific situation.

---

Important Questions to Ask Your Care Team

To better understand your remission status and monitoring plan:

1. What is my current stage, and what does that mean for my risk of recurrence?
2. How often should I have follow-up appointments and imaging tests?
3. What should I do if I notice a new or changing spot on my skin between appointments?
4. Are there any signs or symptoms I should watch for that would require immediate attention?
5. How long will I need follow-up care, and does this change over time?

---

Key Takeaway

Remission is an encouraging milestone, but melanoma requires ongoing vigilance. According to the NCCN Guidelines, your provider should explain how you can do self-exams of your skin and lymph nodes, and regular professional monitoring helps catch any recurrence early — when treatment is most effective.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.